非酒精性脂肪性肝病：分子途径和治疗策略。
Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.
机构信息
Department of Endocrinology and Metabolism, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
出版信息
Lipids Health Dis. 2013 Nov 9;12:171. doi: 10.1186/1476-511X-12-171.
Abstract
Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy will be outlined.
摘要
随着代谢综合征患者数量的增加，非酒精性脂肪性肝病（NAFLD）的患病率也随着肥胖症的流行而相应增加。虽然目前还没有针对 NAFLD 的既定治疗方法，但目前的研究正在针对 NAFLD 及其相关代谢紊乱的潜在分子机制。本文讨论了其中一些新兴的分子机制及其对治疗 NAFLD 的治疗意义。本文将概述确定潜在药物治疗靶点的基础研究。
相似文献
1
Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.
Lipids Health Dis. 2013 Nov 9;12:171. doi: 10.1186/1476-511X-12-171.
2
Nuclear receptors and nonalcoholic fatty liver disease.
Biochim Biophys Acta. 2016 Sep;1859(9):1083-1099. doi: 10.1016/j.bbagrm.2016.03.002. Epub 2016 Mar 4.
3
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Toxicol Appl Pharmacol. 2014 Apr 1;276(1):73-81. doi: 10.1016/j.taap.2014.02.001. Epub 2014 Feb 15.
4
Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
Gastroenterology. 2008 Feb;134(2):556-67. doi: 10.1053/j.gastro.2007.11.037. Epub 2007 Nov 28.
5
Current pharmacological treatment of nonalcoholic fatty liver.
Curr Med Chem. 2006;13(24):2889-900. doi: 10.2174/092986706778521878.
6
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
7
Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Eur J Pharmacol. 2016 Oct 5;788:306-314. doi: 10.1016/j.ejphar.2016.06.043. Epub 2016 Jun 24.
8
Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Int J Mol Med. 2005 Oct;16(4):631-5.
9
Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers.
Cell Metab. 2014 Jan 7;19(1):84-95. doi: 10.1016/j.cmet.2013.11.018.
10
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Trends Endocrinol Metab. 2017 Apr;28(4):250-260. doi: 10.1016/j.tem.2016.11.006. Epub 2016 Dec 13.
引用本文的文献
1
The Potential of Lamiaceae Herbs for Mitigation of Overweight, Obesity, and Fatty Liver: Studies and Perspectives.
Molecules. 2022 Aug 8;27(15):5043. doi: 10.3390/molecules27155043.
2
Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC.
Front Oncol. 2021 Jan 29;10:628506. doi: 10.3389/fonc.2020.628506. eCollection 2020.
3
Effect of dietary oils from various sources on carbohydrate and fat metabolism in mice.
Food Nutr Res. 2020 Aug 13;64. doi: 10.29219/fnr.v64.4287. eCollection 2020.
4
The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Mol Med. 2020 Jun 5;26(1):54. doi: 10.1186/s10020-020-00164-4.
5
Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway.
Acta Pharmacol Sin. 2020 Mar;41(3):383-393. doi: 10.1038/s41401-019-0311-z. Epub 2019 Oct 28.
6
FoxO1 is a critical regulator of hepatocyte lipid deposition in chronic stress mice.
PeerJ. 2019 Sep 27;7:e7668. doi: 10.7717/peerj.7668. eCollection 2019.
7
Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.
J Int Med Res. 2019 Oct;47(10):5239-5255. doi: 10.1177/0300060519859750. Epub 2019 Aug 5.
8
Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver.
Sci Rep. 2019 Jul 22;9(1):10596. doi: 10.1038/s41598-019-46664-0.
9
Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Curr Med Sci. 2019 Feb;39(1):37-43. doi: 10.1007/s11596-019-1997-3. Epub 2019 Mar 13.
10
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ).
Mar Drugs. 2018 Nov 19;16(11):455. doi: 10.3390/md16110455.
本文引用的文献
1
Reversal of obesity-induced hypertriglyceridemia by (R)-α-lipoic acid in ZDF (fa/fa) rats.
Biochem Biophys Res Commun. 2013 Sep 27;439(3):390-5. doi: 10.1016/j.bbrc.2013.08.063. Epub 2013 Aug 29.
2
Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence?
Free Radic Res. 2013 Nov;47(11):854-68. doi: 10.3109/10715762.2013.830717. Epub 2013 Oct 4.
3
Pioglitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain.
BMC Biol. 2013 Aug 1;11:88. doi: 10.1186/1741-7007-11-88.
4
Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
Biochim Biophys Acta. 2013 Dec;1832(12):2085-96. doi: 10.1016/j.bbadis.2013.07.014. Epub 2013 Aug 2.
5
Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.
Gene. 2013 Oct 10;528(2):328-34. doi: 10.1016/j.gene.2013.07.014. Epub 2013 Jul 23.
6
Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease.
Mol Cell Endocrinol. 2013 Oct 15;379(1-2):35-42. doi: 10.1016/j.mce.2013.06.002. Epub 2013 Jun 12.
7
Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice.
PLoS Genet. 2013 May;9(5):e1003483. doi: 10.1371/journal.pgen.1003483. Epub 2013 May 9.
8
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5422-7. doi: 10.1073/pnas.1303360110. Epub 2013 Mar 19.
9
Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.
J Biol Chem. 2013 Apr 26;288(17):11761-70. doi: 10.1074/jbc.M112.446575. Epub 2013 Mar 4.
10
Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis.
DNA Cell Biol. 2013 Apr;32(4):188-98. doi: 10.1089/dna.2012.1947. Epub 2013 Feb 28.
Zotero 插件